Receive The Newest Study Notifications

-- 5F9 Well-Tolerated in Combination with Rituximab -- -- Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached -- -- Overall Response Rate (ORR) of 36% Observed in DLBCL and ORR of 61% Observed in Indolent Lymphoma --...

– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% CR rate and 75%...

The main results from PIONEER 6 were presented at the American Diabetes Association (ADA) 79th Scientific Sessions and simultaneously published in The New England Journal of Medicine (NEJM). Novo Nordisk has announced that the PIONEER 6 trial achieved its primary...

Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive...

Results presented at 24th Congress of EHA in Amsterdam Combination of iadademstat and azacitidine shows good safety profile in elderly AML patients Recommended dose for Phase II established with only six patients Quick onset of response and preliminary clinical...

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology,...

Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability and...

The EndBrainCancer Initiative (EBCI) held its 8thAnnual "Brains Matter" Dinner on May 15th raising $57,500 for its work. The "Hopeless to HOPE" campaign was announced. The goal of this multi-year campaign is to bring new clinical trials for brain cancer to the Greater...

Patients with end-stage renal disease (ESRD) experience extremely high morbidity and mortality, and there are virtually no therapeutic interventions besides dialysis treatment which are proven, in properly designed randomized controlled trials (RCTs), to improve...

-ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile -Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a Partial Response -Partial Response also observed in the study’s first Richter’s...

Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the dosing of the first patient in its...

An analyst called the data, on ZGN-1061, encouraging in a relatively small study but added that more preclinical data will be needed to give a clearer picture of the way forward for the drug. Data from a small clinical trial in Type 2 diabetes may provide a way...

Phase 2 clinical trial is testing TIL therapy against late-stage melanoma Atlantic Health System Cancer Care’s Atlantic Melanoma Center is among the nation’s leading cancer programs participating in the clinical trials of a new type of personalized immunotherapy known...

NRG oncology trial reaffirms carboplatin and paclitaxel chemotherapy alone should remain standard treatment for endometrial cancer The New England Journal of Medicine recently published the primary endpoint of the NRG Oncology clinical trial NRG-GOG 0258, which showed...

LUND, Sweden I June 12, 2019 I BioInvent International AB (BINV) today announces the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with rituximab, currently being...

The Australasian Leukaemia and Lymphoma Group (ALLG) are pleased to announce the launch of the APML5 interim clinical trial results at the 24th Congress of the European Hematology Association (EHA) in Amsterdam in June 2019. The interim results show promise for an...

Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate Based on DSMB clearance, two lead dosage levels have been selected for ongoing Phase 2 clinical development Saint-Herblain (France), June 12, 2019 – Valneva SE (“Valneva” or...

Software is playing a growing role in clinical trials, and over the years it’s been introduced as a tool to help enroll patients, collect data, and analyze results. But one aspect of clinical trial record-keeping has been stubbornly stuck on paper—the reporting of...

Phase 1 study will evaluate the safety and tolerability of TERN-101, an FXR agonist in development for the treatment of NASH FOSTER CITY, Calif. & SHANGHAI--(BUSINESS WIRE)-- Terns Pharmaceuticals, Inc. today announced the initiation of a Phase 1 clinical trial of...

Clinical trials are crucial for new product and device development and are required by the Food and Drug Administration (FDA) before approvals can be granted for their use in the general population. Overall success is dependent on sponsors to supply clinically valid...